Низкодозовый тенектеплаз для лечения острого ишемического инсульта у пациентов пожилого возраста (DATE-AGING)
Эффективность и безопасность низких доз тенектеплазы при лечении острого ишемического инсульта у пожилых пациентов: проспективное, многоцентровое, рандомизированное контролируемое исследование
The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Тип исследования
Тип исследования
Регистрация (Действительный)
Регистрация
Фаза
Фаза
- Фаза 4
Контакты и местонахождение
Места учебы
-
-
-
Anshan, Китай
- Anshan Changda Hospital
-
Anyang, Китай
- Anyang People's Hospital
-
Anyang, Китай
- Huaxian People's Hospital of Henan
-
Baoshan, Китай
- Baoshan People's Hospital
-
Bijie, Китай
- People's Hospital of Zhijin County
-
Chongqing, Китай
- Chongqing University Three Gorges Hospital
-
Chongqing, Китай
- Chongqing University Jiangjin Hospital
-
Chongqing, Китай
- Bishan Hospital
-
Chongqing, Китай
- Chongqing Emergency Medical Center
-
Chongqing, Китай
- Chongqing University Fuling Hospital
-
Chongqing, Китай
- Dianjiang People's Hospital OF Chongqing
-
Chongqing, Китай
- People's Hospital Of Xiushan County
-
Chongqing, Китай
- The People's Hospital of Dazu Chongqing
-
Chongqing, Китай
- The People's Hospital of HeChuan, Chongqing
-
Chongqing, Китай
- The People's Hospital of Rongchang Chongqing
-
Chongqing, Китай
- The People's Hospital of Tongnan District Chongqing City
-
Chongqing, Китай
- The Seventh People's Hospital of Chongqing
-
Chongqing, Китай
- Tongliang Hospital
-
Chongqing, Китай
- Yunyang County People's Hospital
-
Dali, Китай
- Dali Bai Autonomous Prefecture People's Hospital
-
Dazhou, Китай
- Dazhou Central Hospital
-
Deyang, Китай
- The People's Hospital of Zhongjiang
-
Guang’an, Китай
- Guang an People's Hospital
-
Guiyang, Китай
- Guizhou Provincial People's Hospital
-
Guiyang, Китай
- The Second People's Hospital of Guiyang(Guiyang Jinyang Hospital)
-
Ha’erbin, Китай
- The First Affiliated Hospital of Harbin Medical University
-
Hebi, Китай
- Xunxian People's Hospital
-
Heyuan, Китай
- Heyuan People's Hospital
-
Huanggang, Китай
- Qichun People's Hosiptal
-
Jianyang, Китай
- The People's Hospital Of Jianyang City
-
Laixi, Китай
- Laixi People's Hospital
-
Leshan, Китай
- People's Hospital of Leshan
-
Leshan, Китай
- Leshan Geriatric Specialized Hospital
-
Luoyang, Китай
- Luoyang Mengjin People's Hospital
-
Nanchong, Китай
- Nanbu People's Hospital
-
Pujiang, Китай
- Puyang People's Hospital
-
Pujiang, Китай
- The People's Hospital of Nan Le Xian
-
Shangqiu, Китай
- People's Hospital of Ningling County
-
Shangqiu, Китай
- The First People's Hospital of Shangqiu
-
Shaoyang, Китай
- The First People ' S Hospital of Shao Yang
-
Shijiazhuang, Китай
- The People's Hospital of Gaocheng
-
Wuhan, Китай
- Wuhan Puren Hospital
-
Xiangyang, Китай
- Xiangyang NO.1 People's Hospital
-
Yibin, Китай
- The second people's hospital of Yibin
-
Zhumadian, Китай
- Zhumadian Central Hospital
-
Zhuzhou, Китай
- Zhuzhou Central Hospital
-
Zigong, Китай
- Zigong Third People's Hospital
-
Ziyang, Китай
- Ziyang Central Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Китай, 400038
- Southwest Hospital, Chongqing, China
-
-
Heilongjiang
-
Harbin, Heilongjiang, Китай, 150200
- Wuchang People's Hospital
-
-
Henan
-
Zhoukou, Henan, Китай, 466300
- Shenqiu County People's Hospital
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Age ≥ 70 years;
- Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS <4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);
- Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
- Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
- Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
- Informed consent from the patient or surrogate.
Exclusion Criteria:
-
Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemisphere);
-
Acute bleeding diathesis or allergy to tenecteplase, including but not limited to
- Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
- Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
- Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) > 1.7 or Prothrombin time (PT)>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
- Platelet count of below 100×10^9/ L
- Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
- Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days
- Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm
- Neoplasm with increased haemorrhagic risk
- Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial/venous malformations
- History of significant trauma or major surgery within the past 3 months.
- Any known disorder associated with a significant increased risk of bleeding
-
Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);
-
Blood glucose <2.8 mmol/L or >22.22 mmol/L;
-
After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;
-
Seizure at stroke onset;
-
Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;
-
Participation in other clinical trials within 3 months prior to screening;
-
Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Low-Dose Tenecteplase
0.175mg/kg tenecteplase |
Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the low-dose group received tenecteplase (0.175 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 17.5 mg/patient. |
|
Активный компаратор: Standard-Dose Tenecteplase
0.25mg/kg tenecteplase |
Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the standard-dose group received tenecteplase (0.25 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 25 mg/patient. |
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
Временное ограничение: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percentage of participants with major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)
Временное ограничение: At 24 hours
|
National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits. |
At 24 hours
|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
Временное ограничение: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
|
Distribution of Modified Rankin Scale (mRS)
Временное ограничение: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
|
Percentage of Participants With Barthel Index Score ≥95
Временное ограничение: up to 90 days
|
The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome. |
up to 90 days
|
|
EQ-5D-5L score
Временное ограничение: At Day 90±7 days
|
Health-related quality of life (the score on the EuroQol Group 5-Dimension 5-Level [EQ-5D-5L] questionnaire, range, -0.39 to 1, with higher scores indicating better quality of life) |
At Day 90±7 days
|
|
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH)
Временное ограничение: up to 36 hours
|
sICH via criteria adapted from the European Cooperative Acute Stroke Study (ECASS III), defined as any apparent extravascular blood in the brain or within the cranium that is associated with clinical deterioration defined by an NIHSS score increase of four points or more from baseline. |
up to 36 hours
|
|
All-cause mortality
Временное ограничение: up to 90 days
|
All-cause mortality at 90 days |
up to 90 days
|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
Временное ограничение: At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
Соавторы и исследователи
Спонсор
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Действительный)
Первичное завершение
Завершение исследования (Действительный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- 2025IITDA10
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- КСО
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .